1Q 2016 Revenue Growth: +21% to EUR3.9m

AIX-EN-PROVENCE, FRANCE--(Marketwired - Apr 19, 2016) - SuperSonic Imagine (EURONEXT PARIS: SSI) (FR0010526814, PEA-PME eligible), the highly-innovative ultrasound company, today announces its revenue for the 1^st quarter of 2016.

Supersonic Imagine's sales for Q1 2016 totaled EUR3.9m, a growth of +21% compared to Q1 2015, driven primarily by strong growth in France, Asia and EMEA (Europe, Middle East and Africa). At constant currency, Q1 growth was +19% year over year. Sales of products and services accounted for EUR3.4m and EUR474k respectively, or 88% and 12% of sales over the period. Service sales increased by 28%.

Other revenue, essentially consisting of non-recurrent fees related to the Group's technology, totaled EUR226k, compared with EUR139k Q1 2015. SuperSonic Imagine's total revenue was EUR4.1m over the 1^st quarter of 2016, increasing by 22%.

Bernard Doorenbos, SuperSonic Imagine's CEO, says: "The growth rate recorded over this first quarter reflects our ambitions for double digit growth in 2016. This quarter, we worked hard on the implementation of our commercial strategy by specialty: liver and breast. Our first concrete result was the signing of the distribution agreement with Sandhill Scientific for the liver market in the United States. Our strong performance reinforces our confidence in our anticipated results over the coming months."

Next press release: H1 2016 sales, on July 19, 2016

About SuperSonic Imagine
Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer^®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. Aixplorer^® is the only system that can image two types of waves: ultrasound waves ensure excellent image quality and shear waves, which allow physicians to visualize and analyse the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This innovation, ShearWave™ Elastography, significantly improves the detection and characterization of numerous pathologies in several applications including breast, thyroid, liver and prostate. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer^® in the main global markets.

For more information about SuperSonic Imagine, please go to www.supersonicimagine.fr